Ariad Pharmaceuticals Inc fka ARIA

[Moanrch]

ASCO13 MAY 31- JUNE 4: 1)ASCO13 Abstract 7024 Phase II study of combination of hyperCVAD with ponatinib frontline therapy of patients (pts)with(Ph)(ALL).

2)ASCO13 Abstract 7048 Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.

3)ASCO13 presentation: Recently Approved Agents 10:00 AM - 10:20 AM Ponatinib Jorge E. Cortes, MD Fri. May 31

4)ASCO13 Abst 10509 Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST)

5)ASCO13 Abstract TPS7129 EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly CML

6)ASCO13 Abstract 7063 Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia

7)ASCO13 Abstract 7001 8:00-8:15am Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in CML